trastuzumab PH1 ADC

Trastuzumab PH1 ADC is an experimental antibody-drug conjugate (ADC) developed by Akari Therapeutics for oncology applications. It consists of the humanized monoclonal antibody trastuzumab, which targets the human epidermal growth factor receptor 2 (HER2), conjugated to PH1, a novel spliceosome-modulating payload. Unlike traditional ADCs that typically utilize microtubule inhibitors or DNA-damaging agents, the PH1 payload induces RNA mis-splicing within cancer cells. This mechanism leads to the generation of neoantigens and triggers a robust immune response in the tumor microenvironment, characterized by the activation of pro-inflammatory macrophages, neutrophils, and B cells, as well as the expansion of gamma-delta T cells. Preclinical studies in colon cancer models have shown that trastuzumab PH1 ADC achieves superior complete response rates compared to trastuzumab emtansine (Kadcyla) when used in combination with anti-PD-1 checkpoint inhibitors.

Other names

HER2-PH1 ADCHER-2-PH1 ADCHER 2-PH1 ADC